Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

Political prioritisation as a driver of vaccine introduction: Evidence from Nigeria’s HPV rollout

Equitable HPV vaccination for all

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

Tumour-selective oncolytic adenovirus LOAd703 with chemo shows immune activation and promising responses in pancreatic cancer

IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma

WHO regional strategy to enhance cervical elimination in the MENA region

Empowering Women's Health: HPV screening and cervical cancer elimination in Pakistan

The case for global gender-neutral HPV vaccination